Indacaterol

Evidence Level: L5

Predicted Indications: 10

Indacaterol

Pharmacist Assessment Report

Indacaterol: From Obstructive Airway Disease (COPD/Asthma) to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Indacaterol is an inhaled, once-daily, ultra-long-acting beta2-agonist (ultra-LABA), used as a bronchodilator for obstructive airway disease. The TxGNN model predicts it may be effective for nephrogenic syndrome of inappropriate antidiuresis (NSIAD) with a very high score, but no clinical trials and no publications support this prediction, so it remains a model output only.

Quick Overview

Item	Content
Original Indication	Obstructive airway disease (COPD and asthma, based on the published literature; the Health Canada licence records compiled for this report contain no indication text)
Predicted New Indication	Nephrogenic syndrome of inappropriate antidiuresis
TxGNN Prediction Score	0.9954
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 5 of 5)
Number of DINs	5 (marketed: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Indacaterol is a beta2-adrenergic agonist. It relaxes bronchial smooth muscle by activating beta2-receptors and raising intracellular cAMP. Detailed mechanism-of-action data were not available in the drug database records compiled for this report, so this description relies on the drug class and the published literature.

NSIAD is caused by gain-of-function variants in the vasopressin V2 receptor (AVPR2), which also signals through cAMP. This shared second messenger is the only visible link the model may be picking up on. It is not a therapeutic rationale: boosting cAMP signaling would, in theory, increase rather than reduce water-retention signaling. The very high score is therefore not supported by any mechanistic or clinical evidence. It comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for this predicted indication.

Literature Evidence

Currently no related literature available for this predicted indication.

Canada Market Information

DIN	Product Name	Status
02498685	ATECTURA BREEZHALER	Valid
02498707	ATECTURA BREEZHALER	Valid
02498693	ATECTURA BREEZHALER	Valid
02418282	ULTIBRO BREEZHALER	Valid
02501244	ENERZAIR BREEZHALER	Valid

All five authorisations are currently valid, and none are cancelled. Dosage form, manufacturer and approved indication text were not available in the records compiled for this report.

Safety Considerations

Disease associations from the knowledge graph (these come from model-derived drug-disease contraindication links, not from label text): hypertension and hypertensive disorder, long QT syndrome (including familial), sudden cardiac arrest, heart conduction disease, coronary artery disease, epilepsy, hyperglycaemia, diabetes mellitus, diabetic ketoacidosis, potassium deficiency, and thyrotoxicosis, hyperthyroidism and Graves disease.
Drug interactions: 100 interactions were identified. The ones reviewed include:
- Moderate: epinephrine, isometheptene, clarithromycin, famotidine, and several antidiabetic agents (metformin, pioglitazone, acarbose, alogliptin, albiglutide, saxagliptin, canagliflozin, dapagliflozin, chlorpropamide).
- Minor: corticosteroids (hydrocortisone, dexamethasone, triamcinolone, beclomethasone, betamethasone, budesonide) and aprepitant.

For label-based warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone, with no trials or publications. The mechanistic link is unfavourable, because beta2-agonism acting through cAMP could in theory worsen the cAMP-driven water retention in NSIAD. The same applies to the other nine top-ranked predictions: none has clinical evidence. One of them, bronchial disease (rank 7), has substantial Phase 3 support, but it largely restates the drug’s existing marketed use rather than representing new repurposing.

To proceed, the following is needed:

A plausible pharmacological rationale, for example preclinical work in AVPR2 gain-of-function models.
Any clinical or case-level evidence in NSIAD.
The Health Canada package insert, to complete the label-based warnings and contraindications.
A safety assessment for the cardiovascular, metabolic and electrolyte risks noted above, especially in the population affected by NSIAD.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.